- Home
- DXCM vs WAT Comparison
DXCM vs WAT Comparison
Compare DXCM & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- WAT
- Stock Information
- Founded
- DXCM 1999
- WAT 1958
- Country
- DXCM United States
- WAT United States
- Employees
- DXCM N/A
- WAT N/A
- Industry
- DXCM Medical/Dental Instruments
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- DXCM Health Care
- WAT Industrials
- Exchange
- DXCM Nasdaq
- WAT Nasdaq
- Market Cap
- DXCM 28.0B
- WAT 22.5B
- IPO Year
- DXCM 2005
- WAT 1995
- Fundamental
- Price
- DXCM $80.57
- WAT $376.70
- Analyst Decision
- DXCM Buy
- WAT Hold
- Analyst Count
- DXCM 17
- WAT 13
- Target Price
- DXCM $98.00
- WAT $379.00
- AVG Volume (30 Days)
- DXCM 3.2M
- WAT 486.3K
- Earning Date
- DXCM 02-06-2025
- WAT 02-04-2025
- Dividend Yield
- DXCM N/A
- WAT N/A
- EPS Growth
- DXCM 83.21
- WAT N/A
- EPS
- DXCM 1.67
- WAT 10.48
- Revenue
- DXCM $3,954,000,000.00
- WAT $2,905,147,000.00
- Revenue This Year
- DXCM $13.10
- WAT $0.53
- Revenue Next Year
- DXCM $14.74
- WAT $5.65
- P/E Ratio
- DXCM $48.32
- WAT $35.96
- Revenue Growth
- DXCM 16.19
- WAT N/A
- 52 Week Low
- DXCM $62.34
- WAT $279.24
- 52 Week High
- DXCM $142.00
- WAT $397.02
- Technical
- Relative Strength Index (RSI)
- DXCM 59.55
- WAT 52.32
- Support Level
- DXCM $74.50
- WAT $354.37
- Resistance Level
- DXCM $80.83
- WAT $379.00
- Average True Range (ATR)
- DXCM 2.46
- WAT 9.22
- MACD
- DXCM -0.01
- WAT -1.66
- Stochastic Oscillator
- DXCM 86.59
- WAT 52.34
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.